Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "Amine oxidase inhibitors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
N an enzyme that catalyzes the oxidation of amines. monoamine oxidase inhibitor (MAOI), n an agent that blocks the oxidation and deamination of monoamines. The action of the inhibitor may increase the presence of catecholamines, which have antidepressant properties, but it is used for a range of disorders.
Lithium combinations, and uses related thereto
InactiveUS20080107756A1Prevent precipitating manic episodeLessening and preventing riskBiocideNervous disorderNorepinephrine reuptake inhibitorPsychoactive drug
The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.
Owner:NOVEN THERAPEUTICS
Amide compound and application thereof in preparing monoamine oxidase inhibitor
ActiveCN101982170AStable in natureHigh purityOrganic active ingredientsNervous disorderAmine oxidase inhibitorsFluorescence
The invention provides a new amide compound shown as structural formula (I) and application thereof in preparing monoamine oxidase inhibitor. The invention takes phenols compound shown as formula (II) and 2-chloroacetamide shown as formula (III) as reaction substrate, reaction is taken place to obtain amide compound shown as the formula (I), and then fluorescence detection method is used for detecting monoamine oxidase inhibition activity. The method has simple operation process, raw materials are available, and the obtained monoamine oxidase inhibitor has stable properties, and purity is high (more than 99%); compared with the previously researched method of monoamine oxidase inhibitor, the sieved novel amide monoamine oxidase inhibitor has simple structure, and inhibition activity and selectivity on MAO-A and MAO-B are all greatly improved.
Owner:日照新睿招商发展有限公司
Use of beggarweed alkaloid monomer component
InactiveCN103816150AStrong inhibitory activityImproved stress behaviorOrganic active ingredientsNervous disorderAmine oxidase inhibitorsPharmaceutical drug
Owner:LANZHOU UNIVERSITY OF TECHNOLOGY
Medicinal compositions
ActiveUS20060241102A1Shorten the construction periodEffective treatmentBiocideNervous disorderTricyclic antidepressantAmine oxidase inhibitors
The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Application of liquidambar formosana hance fruit tannin monomer
InactiveCN102743367AOrganic active ingredientsNervous disorderGallic acid esterAmine oxidase inhibitors
The invention relates to applications of liquidambar formosana hance fruit tannin monomer. The monomer comprises the components of gallic acid, ethyl gallate, p-digalloyl acid, and ethyl-p-digallate. The invention relates to the application of the monomer in preparing a monoamine oxidase inhibitor. The invention is characterized in that the invention relates to the applications of gallic acid, ethyl gallate, p-digalloyl acid, and ethyl-p-digallate in preparing medicines used for treating depression and Parkinson's disease.
Owner:LANZHOU UNIVERSITY OF TECHNOLOGY
Compositions useful especially for treatment or prevention of metabolic syndrome
InactiveUS20070191408A1Increased glucose uptakeEnhancing glucose uptakeBiocideAnimal repellantsFood additiveAmine oxidase inhibitors
The present invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual in which an effective amount of an amine oxidase enzyme inhibitor is administered to the individual. The invention also relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual in which a vitamin B1, its derivative, its precursor or metabolite is administered to the individual. In addition, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, as well as a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.
Owner:FARON PHARMA OY
Phenylidene phenyl peptide compounds and medicinal composition and application thereof
ActiveCN108752300ANovel structureEasy to synthesizeOrganic active ingredientsNervous disorderMonoamine Oxidase Type BKinase activity
The invention provides phenylidene phenyl peptide compounds, a medicinal composition using the phenylidene phenyl peptide compounds as active components, and application thereof as monoamine oxidase B(MAO-B) inhibitors and application thereof to preparation of medicines for treating Parkinson's disease (PD). Monoamine oxidase B (MAO-B) has been proved to be closely related to the pathogenesis ofthe Parkinson's disease (PD) and is a classic target for research and development of the medicines for treating the Parkinson's disease (PD). The invention provides application of the phenylidene phenyl peptide compounds to preparation of the monoamine oxidase B (MAO-B) inhibitors. In-vitro kinase activity experiments prove that the phenylidene phenyl peptide compounds have a significant monoamineoxidase B (MAO-B) inhibiting effect.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Pharmaceutical composition
InactiveUS8034820B2Effective treatmentShorten the construction periodBiocideNervous disorderTricyclic antidepressantPurine
The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Application of Aphanamixoid A to preparation of monoamine oxidase (MAO) inhibitor
InactiveCN103120673AStrong inhibitory activitySignificant progressOrganic active ingredientsDrug compositionsDiseaseAmine oxidase inhibitors
The invention provides an application of Aphanamixoid A to the preparation of a monoamine oxidase (MAO) inhibitor. Compared with the existing MAO inhibitor, the MAO inhibitor provided by the invention is greatly improved on the aspects of inhibitory activity and selectivity to MAO-A and MAO-B. The application of the Aphanamixoid A to the preparation of the MAO inhibitor, related by the invention, is disclosed for the first time; a framework type of the Aphanamixoid A is brand new, and Aphanamixoid A has unexpected strong inhibitory activity to MAO, so that no possibility that any revelation is given by other compounds exists, and Aphanamixoid A has remarkable substantive features and is also remarkably improved on the aspect of treating MAO imbalance related diseases.
Owner:吴俊华
Methods and compositions for the treatment and diagnosis of haemorrhagic conversion
InactiveUS20120014939A1Increase probabilityPeptide/protein ingredientsMicrobiological testing/measurementAntithrombotic AgentAmine oxidase inhibitors
The invention provides a method for predicting a hemorrhagic disorder in a patient consisting determining amine oxidase and, particularly, VAP-1 in a sample from said patient. The invention also provides pharmaceutical compositions comprising an inhibitor of amine oxidase and an antithrombotic agent as well as the use of an inhibitor of amine oxidase for treatment of hemorrhagic disorders.
Owner:AUTONOMOUS UNIVERSITY OF BARCELONA +1
Inhibitor for monoamine oxidase A
ActiveCN110642766AEasy to operateEasy to follow upOrganic active ingredientsNervous disorderAmine oxidase inhibitorsPtru catalyst
The invention discloses an inhibitor for monoamine oxidase A. The inhibitor for the monoamine oxidase A is obtained by using cheap ruthenium / carbon as a catalyst to catalyze thioether synthesis at room temperature. The method specifically comprises the following steps: by taking a compound represented by a formula (III) shown in the specification as a reaction raw material, the Ru / C as the catalyst, NaIO4 as an oxidizing agent and water as a solvent, performing a reaction at room temperature, and after the reaction is finished, carrying out post-treatment on the reaction solution to obtain thesulfone compound represented by a formula (IV) shown in the specification. According to the method, the water is used as the solvent, the cheap ruthenium / carbon is oxidized by sodium periodate to generate ruthenium tetroxide, so that the thioether compound is further oxidized to synthesize the target product, and the preparation method is more efficient, faster, more environmentally friendly andmilder; and the prepared inhibitor for the monoamine oxidase A has good monoamine oxidase A inhibition activity, can be used for preparing drugs for inhibiting the activity of the monoamine oxidase A,has a wide application prospect in drug development, and is expected to provide a more effective way for treatment of related diseases.
Owner:ZHEJIANG UNIV OF TECH
Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
ActiveUS20170044117A1Potent analgesic effectEffectively inhibits neuropathic mechanical hyperalgesiaNervous disorderOrganic chemistryAmine oxidase inhibitorsBiological activation
The invention relates to a compound having SSAO / VAP-1 inhibitor activity for use in the treatment of hyperalgesia and allodynia implicated in traumatic neuropathy or neurogenic inflammation. Accordingly, the invention relates to a compound having SSAO / VAP-1 inhibitor activity for use in the inhibition of pathological activation and dysfunctions of peptidergic sensory nerves caused by mechanical damage or chemical activation of peptidergic sensory nerves in neurogenic inflammation.
Owner:PECSI TUDOMANYEGYETEM
Diarylethene compound as well as medicine composition and application thereof
ActiveCN110386881ANovel structureEasy to synthesizeNervous disorderOrganic chemistryChemical synthesisMonoamine Oxidase Type B
The invention discloses a diarylethene compound as well as a medicine composition and application thereof and relates to the technical field of medicines. The invention provides the diarylethene compound, and the structural formula (I) of the diarylethene compound is shown in the specification. The diarylethene compound disclosed by the invention has a remarkable monoamine oxidase B (MAO-B) inhibition function, and can be used for preparing monoamine oxidase inhibitors B and Parkinson's disease prevention medicines. The invention further provides the medicine composition with the diarylethenecompound as an active component. The medicine composition can be used as a monoamine oxidase B (MAO-B) inhibitor and a Parkinson's disease treatment medicine. In addition, the diarylethene compound disclosed by the invention is novel in structure, easy in chemical synthesis, low in cost and small in side effect.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Application of a kind of coumarin compound in the preparation of monoamine oxidase inhibitor
InactiveCN108478568BNervous disorderHeterocyclic compound active ingredientsAmine oxidase inhibitorsMonoamine Oxidase A Gene
Owner:HUAZHONG AGRI UNIV
Methods and compositions for the treatment and diagnosis of haemorrhagic conversion
InactiveUS8906642B2Peptide/protein ingredientsMicrobiological testing/measurementAntithrombotic AgentAmine oxidase inhibitors
Owner:UNIV AUTONOMA DE BARCELONA +1
Use of a 1,3-benzoxathiol-2-one compound in the preparation of monoamine oxidase inhibitors
InactiveCN108379260BNervous disorderHeterocyclic compound active ingredientsMonoamine Oxidase Type BAmine oxidase inhibitors
The invention discloses an application of 1,3-benzoxazolethiol-2-one compounds, which are shown as Formula (I), in preparing a monoamine oxidase inhibitor. Based upon in-vitro enzymatic activity experimental tests, it is indicated that the compounds have good inhibitory activity on both monoamine oxidase A and monoamine oxidase B; therefore, a reference and a new thought are provided and developedfor the development of the novel MAO inhibitor (monoamine oxidase inhibitor) (shown as the Description).
Owner:HUAZHONG AGRI UNIV
Preparation method and application of monoamine oxidase A inhibitor
InactiveCN110693963AHigh extraction rateIncrease the scope of applicationNervous disorderPlant ingredientsRefluxAmine oxidase inhibitors
Owner:SICHUAN ACAD OF CHINESE MEDICINE SCI
Methods for the treatment of skin neoplasms
Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.
Owner:TEIKOKU SEIYAKU KK TEIKOKU SEIYAKU CO LTD
A kind of preparation method of monoamine oxidase inhibitor
ActiveCN105693515BImprove securityNatural Sources ExpansionNervous disorderMicroorganism based processesAmine oxidase inhibitorsOxidative enzyme
The invention discloses a preparation method of a monoamine oxidase inhibitor. The preparation method comprises following steps: (1) ethyl alcohol is used for precipitating a lactobacillus fermentation broth, and a supernatant is collected; (2) water and ethyl acetate are added into the supernatant for extraction, an obtained ethyl acetate phase extracting solution is subjected to evaporation so as to remove the solvent and obtain an ester phase extract; and (3) the ester phase extract obtained in step (2) is subjected to column chromatography positive phase elution. The monoamine oxidase inhibitor is prepared from natural products, is obtained via separation purification from lactobacillus fermentation products, is low in toxicity, high in safety, and possesses a promising application prospect.
Owner:BRIGHT DAIRY & FOOD CO LTD
Preparation method of monoamine oxidase inhibitor
ActiveCN105693515AImprove securityNatural Sources ExpansionNervous disorderMicroorganism based processesEthanol precipitationEvaporation
The invention discloses a preparation method of a monoamine oxidase inhibitor. The preparation method comprises following steps: (1) ethyl alcohol is used for precipitating a lactobacillus fermentation broth, and a supernatant is collected; (2) water and ethyl acetate are added into the supernatant for extraction, an obtained ethyl acetate phase extracting solution is subjected to evaporation so as to remove the solvent and obtain an ester phase extract; and (3) the ester phase extract obtained in step (2) is subjected to column chromatography positive phase elution. The monoamine oxidase inhibitor is prepared from natural products, is obtained via separation purification from lactobacillus fermentation products, is low in toxicity, high in safety, and possesses a promising application prospect.
Owner:BRIGHT DAIRY & FOOD
A monoamine oxidase inhibitor
ActiveCN110642766BEasy to operateEasy to follow upOrganic active ingredientsNervous disorderAmine oxidase inhibitorsPtru catalyst
The invention discloses a monoamine oxidase A inhibitor, which is obtained by using cheap ruthenium carbon as a catalyst to catalyze the synthesis of thioether at room temperature, specifically: using the compound represented by formula (III) as the reaction raw material, Ru / C as catalyst, NaIO 4 is an oxidant, water is a solvent, and the reaction is carried out at room temperature. After the reaction is completed, the reaction liquid is post-treated to obtain the sulfone compound shown in formula (IV). The method of the invention uses water as a solvent, oxidizes cheap ruthenium carbon with sodium periodate to generate ruthenium tetroxide, and further oxidizes the sulfide compound to synthesize the target product, and the preparation method is more efficient, quick, environmentally friendly and mild. The prepared monoamine oxidase A inhibitor has good monoamine oxidase A inhibitory activity, can be used to prepare a drug for inhibiting the activity of monoamine oxidase A, and has broad application prospects in drug development, in order to provide a more effective way for the treatment of related diseases.
Owner:ZHEJIANG UNIV OF TECH
Use of an isoindole-1,3-dione compound in the preparation of monoamine oxidase inhibitors
Owner:HUAZHONG AGRI UNIV
Application of Tibetan medicine duhat fruit tannin monomer
InactiveCN103816142AOrganic active ingredientsNervous disorderGallic acid esterAmine oxidase inhibitors
The invention relates to application of a Tibetan medicine duhat fruit tannin monomer, and in particular relates to application of a duhat fruit tannin monomer consisting of gallic acid, methyl gallate and 3,4,8,9,10-pentahydroxydibenzo[b,d]pyran-6-one in preparing a monoamine oxidase inhibitor. The application is characterized in that gallic acid, methyl gallate and 3,4,8,9,10-pentahydroxydibenzo[b,d]pyran-6-one are applied to preparation of medicines for treating depression and Parkinson disease.
Owner:LANZHOU UNIVERSITY OF TECHNOLOGY
Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
ActiveUS9790193B2Effectively inhibits neuropathic mechanical hyperalgesiaReduce heatNervous disorderOrganic chemistryAmine oxidase inhibitorsBiological activation
Owner:PECSI TUDOMANYEGYETEM
Use of a 5h-thiazolo[3,2-a]pyrimidin-5-one compound in the preparation of monoamine oxidase inhibitors
The invention discloses the use of 5H-thiazolo[3,2-a]pyrimidin-5-one compounds with the structure shown in formula (I) in the preparation of monoamine oxidase inhibitors. After in vitro enzyme activity test, the compounds It has good inhibitory activity on monoamine oxidase A and B, which provides reference and inspires new ideas for the development of new MAO inhibitors.
![Use of a 5h-thiazolo[3,2-a]pyrimidin-5-one compound in the preparation of monoamine oxidase inhibitors](https://images-eureka.patsnap.com/patent_img/d2017bdf-1965-4034-976a-e4559307b7eb/FDA0002597265960000011.png "Use of a 5h-thiazolo[3,2-a]pyrimidin-5-one compound in the preparation of monoamine oxidase inhibitors")
![Use of a 5h-thiazolo[3,2-a]pyrimidin-5-one compound in the preparation of monoamine oxidase inhibitors](https://images-eureka.patsnap.com/patent_img/d2017bdf-1965-4034-976a-e4559307b7eb/BDA0002597265970000021.png "Use of a 5h-thiazolo[3,2-a]pyrimidin-5-one compound in the preparation of monoamine oxidase inhibitors")
![Use of a 5h-thiazolo[3,2-a]pyrimidin-5-one compound in the preparation of monoamine oxidase inhibitors](https://images-eureka.patsnap.com/patent_img/d2017bdf-1965-4034-976a-e4559307b7eb/BDA0002597265970000026.png "Use of a 5h-thiazolo[3,2-a]pyrimidin-5-one compound in the preparation of monoamine oxidase inhibitors")
Owner:HUAZHONG AGRI UNIV
Methods for the treatment of skin neoplasms
ActiveUS9913812B2Heavy metal active ingredientsEster active ingredientsAmine oxidase inhibitorsSkin Neoplasm
Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.
Owner:TEIKOKU SEIYAKU KK TEIKOKU SEIYAKU CO LTD
Method of reducing neuronal cell damage
InactiveCN103479603AImmediate or extended release formulationsSenses disorderNervous disorderTricyclic antidepressantAmine oxidase inhibitors
The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and / or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and / or ischemic condition; and within 16 hours after onset of the condition, administering to the subject a neuroprotective amount of a pharmaceutical agent. The pharmaceutical agent is preferably selected from the group consisting of: a central nervous system stimulant (CNSS), monoamine neurotransmitter, monoamine oxidase inhibitor (MAOI), tricyclic antidepressant (TCA), or a combination thereof. Preferred agents include amphetamines, methamphetamine, methylphenidate, methylenedioxymethamphetamine, or a combination thereof.
Owner:UNIVERSITY OF MONTANA
Applications of 1-tetralone compound in preparation of monoamine oxidase inhibitors
InactiveCN111904956AMonoamine oxidase ACtiveOrganic active ingredientsNervous disorderAmine oxidase inhibitorsTetralone
The invention discloses applications of 1-tetralone compound in preparation of monoamine oxidase inhibitors. The structure of the compound is shown as a formula (I). Through enzyme activity test in vitro, the compound can have good inhibitory activity on monoamine oxidase A and B, so that reference and new inspiring ideas can be provided for the development of novel MAO inhibitors.
Owner:HUAZHONG AGRI UNIV
Compositions useful especially for treatment or prevention of metabolic syndrome
This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.
Owner:BIOTIE THERAPIES CORP
Use of a thiadiazolotriazine compound in the preparation of monoamine oxidase inhibitors
InactiveCN108295074BHas monoamine oxidase inhibitory activityHas inhibitory activityNervous disorderOrganic chemistryAmine oxidase inhibitorsMedicine
The invention discloses the application of a triazine compound shown as a structural formula (I) in the preparation of a monoamine oxidase inhibitor. Through in vitro enzyme activity experimental measurement, the compound has good inhibitory activity for monoamine oxidase-B, so that reference is provided for developing a novel MAO inhibitor, and a new thought is inspired.
Owner:HUAZHONG AGRI UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com